Fate Therapeutics Stock Analysis
| FATE Stock | USD 2.07 0.15 6.76% |
Fate Therapeutics is undervalued with Real Value of 3.36 and Target Price of 7.28. The main objective of Fate Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Fate Therapeutics is worth, separate from its market price. There are two main types of Fate Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Fate Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Fate Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Fate |
Fate Stock Analysis Notes
About 98.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fate Therapeutics recorded a loss per share of 1.64. The entity had not issued any dividends in recent years. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Fate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 542 people. To learn more about Fate Therapeutics call Scott Wolchko at 858 875 1800 or check out https://www.fatetherapeutics.com.Fate Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Fate Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Fate Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Fate Therapeutics generated a negative expected return over the last 90 days | |
| Fate Therapeutics has high historical volatility and very poor performance | |
| Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 63.53 M. Net Loss for the year was (160.93 M) with loss before overhead, payroll, taxes, and interest of (224.15 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock |
Fate Therapeutics Upcoming and Recent Events
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Fate Largest EPS Surprises
Earnings surprises can significantly impact Fate Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-15 | 2017-03-31 | -0.2 | -0.24 | -0.04 | 20 | ||
2016-05-09 | 2016-03-31 | -0.25 | -0.29 | -0.04 | 16 | ||
2021-05-05 | 2021-03-31 | -0.43 | -0.48 | -0.05 | 11 |
Fate Therapeutics Environmental, Social, and Governance (ESG) Scores
Fate Therapeutics' ESG score is a quantitative measure that evaluates Fate Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Fate Therapeutics' operations that may have significant financial implications and affect Fate Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Fate Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Johnson & Johnson | 2024-06-30 | 3.4 M | Baker Bros Advisors Lp | 2024-09-30 | 3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.6 M | Assenagon Asset Management Sa | 2024-09-30 | 2.4 M | Goldman Sachs Group Inc | 2024-06-30 | 2.3 M | Geode Capital Management, Llc | 2024-06-30 | 2.2 M | Vestal Point Capital Lp | 2024-06-30 | 2 M | Bank Of America Corp | 2024-06-30 | 2 M | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 1.7 M | Redmile Group, Llc | 2024-09-30 | 13.2 M | Vanguard Group Inc | 2024-09-30 | 10.4 M |
Fate Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 252.84 M.Fate Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | (0.44) | (0.46) |
Management Efficiency
Fate Therapeutics has return on total asset (ROA) of (0.2211) % which means that it has lost $0.2211 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4659) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, Fate Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 15.3 M, whereas Other Assets are forecasted to decline to 0.95.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.74 | 1.90 | |
| Tangible Book Value Per Share | 3.74 | 1.90 | |
| Enterprise Value Over EBITDA | (2.50) | (2.62) | |
| Price Book Value Ratio | 1.00 | 0.95 | |
| Enterprise Value Multiple | (2.50) | (2.62) | |
| Price Fair Value | 1.00 | 0.95 | |
| Enterprise Value | 429.7 M | 408.2 M |
Understanding the operational decisions made by Fate Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin (17.04) | Beta 1.879 | Return On Assets (0.22) | Return On Equity (0.47) |
Technical Drivers
As of the 22nd of November, Fate Therapeutics shows the Standard Deviation of 4.95, mean deviation of 3.97, and Variance of 24.53. Fate Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Fate Therapeutics market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Fate Therapeutics is priced favorably, providing market reflects its regular price of 2.07 per share. Please also check Fate Therapeutics jensen alpha, which is currently at (0.86) to verify the company can sustain itself at a future point.Fate Therapeutics Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Fate Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Fate Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Fate Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fate Therapeutics Outstanding Bonds
Fate Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fate Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fate bonds can be classified according to their maturity, which is the date when Fate Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Fate Therapeutics Predictive Daily Indicators
Fate Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fate Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Fate Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 25th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 21st of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 30th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 21st of August 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 13th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Fate Therapeutics Forecast Models
Fate Therapeutics' time-series forecasting models are one of many Fate Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fate Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Fate Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Fate Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Fate Therapeutics. By using and applying Fate Stock analysis, traders can create a robust methodology for identifying Fate entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (2.53) | (2.66) | |
| Operating Profit Margin | (3.00) | (3.15) | |
| Net Loss | (2.53) | (2.66) | |
| Gross Profit Margin | (1.55) | (1.62) |
Current Fate Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Fate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Fate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 7.28 | Buy | 17 | Odds |
Most Fate analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Fate stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Fate Therapeutics, talking to its executives and customers, or listening to Fate conference calls.
Fate Stock Analysis Indicators
Fate Therapeutics stock analysis indicators help investors evaluate how Fate Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Fate Therapeutics shares will generate the highest return on investment. By understating and applying Fate Therapeutics stock analysis, traders can identify Fate Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 76.6 M | |
| Common Stock Shares Outstanding | 98.4 M | |
| Total Stockholder Equity | 368.4 M | |
| Property Plant And Equipment Net | 158.5 M | |
| Cash And Short Term Investments | 315.2 M | |
| Cash | 41.9 M | |
| Accounts Payable | 4.7 M | |
| Net Debt | 61.7 M | |
| 50 Day M A | 3.057 | |
| Total Current Liabilities | 39.1 M | |
| Other Operating Expenses | 254 M | |
| Non Current Assets Total | 174.7 M | |
| Non Currrent Assets Other | 15.2 M | |
| Stock Based Compensation | 43.5 M |
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |